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Abstract
Influenza vaccine production in embryonated eggs is associated with many disadvantages, and production in cell culture systems is a viable alternative. 
Introduction
Influenza viruses A and B are enveloped RNA viruses, whose genome consists of eight segments of linear negative-sense, single-stranded RNA. They are the causative agents of acute respiratory disease and are responsible for over 40,000 deaths [1] and 100,000
hospitalizations [2] in the US per year. Immunization remains the most efficient strategy of prevention against influenza and currently more than 250 million doses of inactivated influenza vaccines are being brought to the market every year [3] . Influenza vaccines include representative strains of influenza A (H1N1 and H3N2) and influenza B viruses.
Due to the high antigenic drift, influenza vaccine composition is adjusted annually based on information collected by various National Influenza Centers worldwide and the recommendations on the World Health Organization [4] .
At present, influenza vaccines are derived from virus propagation in embryonated chicken eggs, a procedure that is time-consuming and labor-intensive. Moreover, immunization with egg-derived vaccines is associated with sensitization against egg proteins and it is contraindicated in subjects with a known history of egg-allergy [5] .
Therefore alternative vaccine production methods, devoid of the drawbacks of the in ovo system are required.
The most attractive method for influenza vaccine production is mammalian cell culture systems, such as Madin Darby canine kidney (MDCK) cells [4, [6] [7] [8] . The original MDCK cell line was established in 1958 by Madin & Darby [9] and a few years later it was recognized that MDCK cells are readily permissive for a wide variety of flu strains [10, 11] .
A major safety concern associated with influenza and other vaccines and host prion protein could have the potential to support propagation of TSE agents [12] .
Therefore testing the prion replication competence of cell lines used for preparation of drugs intended for human -or animal -use becomes imperative.
The goal of the current study was to test whether MDCK cells are capable of replicating prions. Several different MDCK cell sublines exist, most of which exhibit an epithelial-like phenotype [13] . Starting from such a subline, that is MDCK 666, we have previously 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 5
Materials and Methods
Cell lysates, Immunoprecipitation and Western Blotting
The MDCK 33016-PF cell line was grown adherently in presence of 2% FCS for all analyses except for the scrapie cell assays (SCA) and infection with influenza virus, where no FCS was added. Cells were washed twice with PBS and then detached by scraping. Cells were centrifuged and then lysed in different buffers containing proteinase inhibitors (Roche, Complete Mini, protease inhibitor cocktail, prod. no. 11836153001).
Lysates intended for Western blot or ELISA were prepared in RIPA buffer (50mM Tris pH 7,4, 1% NP40, 0.25% deoxycholic acid sodium salt, 150mM NaCl, 1mM EGTA).
Total protein concentration was estimated using a standard colorimetric method based on bicinchoninic acid (Pierce Biotechnology, Rockford, IL, USA). For immunoprecipitation experiments, lysates were prepared in PBS with 1% NP40 and 0.25% deoxycholate. After two rounds of snap freezing and thawing, the cell debris were precipitated by centrifugation at 500 g for 3 min and the supernatants were collected. For western blots, 100µg of total proteins per well were analyzed on a NuPAGE 12% BisTris gel (Invitrogen, prod. no. NP0342BOX). The proteins were transferred to a nitrocellulose membrane, blocked with 5% Top Block (Fluka), and then probed with primary antibodies. POM1 (2mg/mL, 1:10000), POM11 (1mg/mL, 1:5000), biotinylated POM1 (1mg/mL, 1:1000) and POM2 (1mg/mL, 1:5000) were used to detect PrP C and a monoclonal antibody against actin (Chemicon, Cat no. MAB1501R, 1mg/mL, 1:8000) was used for loading control. For secondary antibodies anti-mouse IgG1-HRP (Zymed, 1mg/mL, 1:18000) and avidin-HRP (BD Biosciences Pharminogen, prod. no. 554058, 1:7000) were used. Blots were developed by using HRP substrate (enhanced chemiluminescent substrate; Pierce), and signals were acquired with Versadoc 3000
imaging system (Bio-Rad, Hercules, CA, USA 
Flotation assay
We used two different protocols for the flotation assay. In the first protocol, we used
OptiPrep for the gradient and in the second one we used Nycodenz. In protocol 1, cells were grown in 150mL flasks to confluency. They were washed twice with ice cold PBS and then scraped in 1mL ice cold MBS buffer (25mM MES (pH 7), 150mM NaCl, 2mM
EDTA and protease inhibitors) and kept on ice for all following steps. Cells were homogenized by passing through a 26G needle, 10-12 times and then centrifuged at 1000g for 5 minutes. 500µL of the supernatant was collected and mixed with 500µL of MBS buffer. It was then sonicated 6 times for 5 sec and after one minute, another six then added on the sample. The gradients were centrifuged for 5 hours at 32'000 rpm (180,000 g) with a sw32 rotor in a Beckman Ultracentrifuge at 4°C. 12 fractions were collected and the proteins were acetone-precipitated. 300µL of the samples were mixed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 7
spinning at 16,000 g for 20 min at 4°C, supernatants were discarded and pellets were air-dried. Pellets were then resuspended with 80µL loading buffer and boiled for 4 min at 95°C. The fractions were loaded on a 12%NuPAGE gel. Prion protein was detected with POM-1 (1:10,000) and the raft fractions were confirmed by detection of Flotillin with a purified mouse anti-flotillin antibody (BD Biosciences Pharmingen, cat. nr: 610821; dilution 1:10,000).
Flotation of detergent-insoluble complexes with Nycodenz was performed as described by Naslavsky et al [14] . were produced and purified as described previously [15] . 
Flow cytometric analysis
Immunocytochemistry
For immunostaining, 10-10,000 cells were grown in gelatin coated chamber slides for 4
days. The cells were rinsed with PBS and fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature followed by 10 min of incubation with NH 4 Cl (20mM in PBS).
After 10 min of blocking in 5% goat serum and PBS, the cells were incubated with POM- Page | 10 agarose gel (1.5%). The bands were cut from the gel and purified with the Qiagen gel extraction kit (cat. no. 28104). 100ng was sent to be sequenced.
Influenza infection of MDCK 33016 cells
The seed virus preparations, which were used for the infection of the MDCK 33016 cells, Infection kinetic of the influenza virus and virus yields were followed by a staining of influenza infected cells with an anti-influenza antibody (Imagen prod. No K610511-2; DAKO Cytomation; Germany) and by quantification in a standard hemagglutination (HA) assay using chicken red blood cells.
Prion infection and scrapie cell assay (SCA)
N2aPK1 cells (17,000 per well), MDCK 33016 (15,000 per well; grown without FCS) and
HpL cells (8000 per well) were plated on a micro-titer 96-well plate and were grown for [16, 17] . In addition, two out of the four CJD samples have been independently inoculated in transgenic mice carrying the human PRNP gene and presence of prion infectivity was confirmed in vivo (data not shown).
The cells were grown to confluency and then (approximately after three days) they were split 1:3. The medium was taken off and kept under sterile conditions. The cells were detached with 30µL EDTA (2mM) for 20 min at 37°C. The old medium was put back and the cells were further detached by pipetting up and down 20-30 times, 100µL were transferred to a new plate and filled up with fresh medium. This was repeated twice.
Cells were further split 1:10 several times with completely fresh medium, in order to remove any residual inoculum. The first assay was completed after 3x 1:3 and 3x 1:10 splits and repeated after several more splits.
All solutions used for the assay were filtered in advance. The plates (Millipore, MultiScreen sterile white plates cat. no. S2EM004M99) were activated by adding 50µL of pure ethanol (70%) to each well for 1 min, sucked off -using a vacuum pump and rinsed twice with 160µL of PBS. The cells were suspended in 300µL of medium and 80µL
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Results
Characterization of PrP C in MDCK cells
Expression of PrP C is a prerequisite for any cell or organism to support prion replication [18] thus is a crucial determinant of prion infectability of MDCK cells. We have recently developed and characterized a panel of high affinity monoclonal antibodies with epitopes that span the entire murine prion protein (mPrP C ) [16] . We have used two of these antibodies, designated POM1 (epitope within amino acids [aa] 121 to 230) and POM11
(epitope aa 64 to 72 and 72 to 80) on a standard Western blotting protocol. In Figure 1A we compared equal amounts of total protein (100µg) Figure 1) .
We next wanted to determine DNA and amino acid sequences of Prnp and PrP 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 15 secondary structure of PrP C , but we think that they probably represent natural polymorphic sites on dog PrP C .
Subcellular localization of PrP C on MDCK cells
Cell-surface localization of PrP C has been shown to be necessary for prion infection of cells in vitro [21] and for neurotoxicity and prion pathology in vivo [22] . We used flow cytometry to verify that PrP C is properly localized on the cell surface of MDCK cells. In Figure 2A we compared the different cell lines using POM2, previously shown to bind native, cell-bound PrP C in flow cytometry (data not shown). We found that MDCK cells Physiologically PrP C was found to be attached to the plasma membrane by a glycosylphosphatidylinositol (GPI)-anchor, in all cells and tissues tested so far. Like most GPI-linked proteins, PrP C resides in cholesterol-enriched microdomains of cell membranes, often referred to as lipid rafts [14] . Following extraction in cold Triton X-100
and ultracentrifugation on density gradients, proteins associated with lipid rafts float in the uppermost fractions. Since proper subcellular localization of PrP C in lipid rafts is very 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 16 Figure 3C ) and found no significant differences. This indicates that failure of cPrP C to associate with raft fractions occurs only within MDCK-cells, presumably due to the very low PrP C in these cells.
Monitoring of PrP C expression levels in MDCK cells during influenza infection
Expression of PrP C as well as several other proteins can be affected by manipulations that have an impact on cell cycle, metabolism and generally cell homeostasis. It is known that induction of stress in any cell may result in up-or down-regulation of genes.
It is conceivable that influenza virus infection of MDCK-cells may lead to an uncontrolled up-regulation of Prnp, as well as other genes, in response to the stress induced by the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 17 Our results indicate that influenza virus infection does not cause any increase in PrP C levels neither in the cells, nor in their supernatant. On the contrary, it seems that virus infection may lead to a decrease in the amounts of PrP C , which is likely a consequence of the harmful effects of the virus on the cells, leading to increased proteolytic activity. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 At first, cells were exposed to a prion-containing brain homogenate, diluted in growth medium for 3 days. After several splits, in which the original inoculum is sufficiently diluted, cells are transferred on an ELISPOT plate, where they were subjected to limited proteolysis which digests PrP C . The presence of the pathologic isoform, the scrapie prion protein (PrP Sc ), which is proteinase resistant, is then detected using a specific anti-PrP antibody on a chemiluminescence-based assay.
We have used RML prions which are readily replicated in vitro by the neuroblastoma cell line, N2aPK1, which serves as a positive control for our experiments. Moreover, the hippocampal cell line HpL, which was derived from Prnp -/-cells, is a negative control, since those cells lack PrP C , which is the required substrate for prion replication and are thus resistant to prions. We repeatedly found that the only cell line giving a positive signal in this assay is N2aPK1 cells, whereas both MDCK-cells and the PrP C -deficient HpL cells seem to be resistant to RML-prions (Figure 5A and B; representative of six independent experiments).
Next, we expanded N2aPK1 and MDCK 33016 cells that have been exposed to RML prions and we prepared lysates, which we used to assess the presence of PrP Sc by an independent method. We performed proteinase K (PK) digestion and analyzed the Sc from the cell lysates, using phosphotungstate (NaPTA) precipitation, thereby increasing the sensitivity of detection ( Figure 5C ). Again, we failed to detect any PK-resistant material in the MDCK cell lysates ( Figure 5C , upper panel) whereas N2aPK1 cells were positive ( Figure 5C , lower panel).
We then went on to exclude the possibility that a phenomenon called the 'species barrier', which is observed in vivo accounted for the apparent resistance of MDCK-cells to mouse adapted scrapie prions. Species barrier refers to the fact that prions isolated from one species are often less infectious to other species, as evident by longer incubation times and reduced attack rates in experimental animals. This is thought to depend on dissimilar host prion protein sequences, thereby hindering the conversion process. Upon serial passages, incubation times gradually decrease, a phenomenon called "adaptation". In some cases the species barrier is so strong that certain hosts do not show any clinical disease upon inoculation of prions from other species.
Nevertheless, brain isolates of these apparently resistant hosts can transmit disease when inoculated to susceptible hosts [23, 24] . For this reason, we wanted to assess whether lysates from MDCK-cells (carrying canine PrP C ) exposed to RML prions (originated from murine PrP C ) may contain infectivity that would only be apparent in a second passage of infection on MDCK-cells. In other words, we wanted to check whether a phenomenon like adaptation may occur in the cells.
We exposed MDCK 33016, N2aPK1 and HpL cells to cell-lysates prepared from RMLinoculated MDCK or N2aPK1 cells. We did not detect any infectivity in the MDCK cell lysates, regardless of whether they were used to infect N2aPK1 or MDCK cells.
Moreover, MDCK cells were resistant to infection by RML-infected N2aPK1-cell lysates ( Figure 5D ). The latter, however evidently carried prion infectivity, since they could infect
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N2aPK1 cells ( Figure 5D ). The detection limit of infectivity derived from cell-lysates was determined to be 10 -5 cell lysate (Supplementary Figure 3) .
SCA using Creutzfeldt-Jakob disease samples
Next we tested whether MDCK 33016 cells could be infected with CJD prions. We have chosen a variety of brain tissue samples from the tissue bank of the National Reference
Center for Prion Diseases (NRPE). The samples we used for infecting MDCK-cells have been extensively characterized previously by immunohistochemistry and Western Blot analysis and the CJD diagnosis was definite [16, 17] . In addition, two of the four samples have been independently inoculated in transgenic mice carrying the human PRNP gene and presence of prion infectivity was confirmed in vivo (data not shown).
All samples used for inoculations were derived from sporadic CJD cases (sCJD). In 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 21 position 134; numbering of cPrP C is 5 amino acids shifted when compared to human).
sCJD samples chosen for MDCK cell infections, were controlled for carrying prion infectivity in vivo by transmission to transgenic mice overexpressing the human prion protein (data not shown).
We first analyzed the sCJD samples in SCA by limiting dilution in order to define the sensitivity of SCA in the case of CJD (data not shown). We found that a 10 -3 dilution of wet brain tissue is ideal for detection by SCA, whereas 10 -5 was in most cases the detection limit of this assay. For infecting the cells, 10 -3 dilution was used, since this is the highest dose that does not harm the cells and was therefore used for all further experiments.
SCA results of the CJD inoculation experiments showed that neither MDCK 33016, nor We went on to check whether a phenomenon like adaptation may occur in the CJDinoculated cells, following a similar protocol as for the RML-infected cells. We exposed MDCK 33016 cells to cell lysates prepared from sCJD-infected either MDCK or N2aPK1 cells. We did not detect any infectivity in the MDCK cells after incubation of sCJDinoculated MDCK 33016 cell-lysates ( Figure 6C ). Moreover, MDCK cells were resistant to infection by sCJD-inoculated N2aPK1-cell lysates ( Figure 6C ). Furthermore, in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 23
Discussion
Immunization remains the most efficient strategy of prevention against influenza. At present, influenza vaccines are prepared in embryonated chicken eggs, a procedure that has many disadvantages. Firstly, it is time-consuming, labor-intensive, and uneconomical since it requires 1-2 eggs per dose of vaccine produced [3] . Moreover, cultivation of influenza viruses in eggs was shown to select for mixed subpopulations which can be antigenically distinct from each other and from the original strain, potentially compromising egg-derived vaccine efficacy [25] . Finally, immunization with egg-derived vaccines can elicit sensitization to egg proteins, such as ovalbumin. Their presence in vaccines may be linked to adverse effects and subjects with a known history of egg allergy are currently excluded from influenza vaccination programs. Since influenza vaccines are intended for annual re-immunization, the repeated administration may lead to immune reactions against egg proteins, leading to a reduced tolerability profile of the product [5] . For all the above reasons, influenza vaccine production in chicken eggs is far from optimal.
In the recent years, a highly pathogenic avian influenza virus A of the subtype H5N1, has affected humans. This virus has the potential to become the next pandemic strain either unchanged or after reassortment with human influenza viruses A [26] . Luckily, avian influenza virus seems to spread poorly among humans and has not caused a pandemic yet, although since 2003 it has claimed the lives of 165 people worldwide [27] .
However, due to continuous mutagenesis (antigenic drift) and genetic reassortment (antigenic shift) of the virus, concerns for a new influenza pandemic have not ceased. In case of a new influenza pandemic, alternative methods of vaccine production, superior in terms of speed, reliability consistency and flexibility of the manufacturing process as well as the efficiency and safety of the final product will become essential.
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The most attractive alternative method for influenza vaccine production relies on mammalian cell cultures. Several cell lines such as Madin Darby canine kidney (MDCK)
cells [4, 6, 7] , African green monkey kidney Vero cells [28] , human retina-derived cell line Per.C6 [29] and St. Jude porcine lung cells (SJPL) [30] have been tested for the production of influenza vaccines. While all those cell lines have major advantages towards the conventional egg-based vaccine production method, MDCK cell line is arguably the best-characterized cell culture system for influenza virus replication [9] .
MDCK cells are readily permissive for a wide variety of flu strains [10, 11] and lately optimal conditions for growing an influenza vaccine in MDCK cell line cultivated in a serum-free medium were determined [7] . Comparison of egg-to MDCK-grown influenza vaccine showed that the latter induced superior protection of ferrets against subsequent challenge with infectious virus grown in either host cell type [6] .
A major safety concern associated with influenza and other vaccines and biopharmaceuticals produced in mammalian cells refers to the risk of replicating prions the infectious agents of transmissible spongiform encephalopathy (TSE), invariably fatal neurodegenerative diseases such as scrapie of sheep, bovine spongiform encephalopathy (BSE) of cattle, and Creutzfeldt-Jakob disease (CJD) of humans. BSE has been transmitted to humans through the consumption of contaminated beef, resulting in the emergence of a new human prion disease, named variant CJD (vCJD), affecting predominantly young adults [31] . Following the occurrence of BSE in three continents since 1986 [32] [33] [34] the need to ensure the TSE safety of vaccines has become vital. One approach is to avoid, whenever possible, tissues from animals, risk tissues and tissues of unknown or uncertain provenance [35] . While this is a reasonable strategy, it is not always feasible to exclude the possibility that any of the material used for vaccine production e.g. cell-culture media and additives, viruses or even the cell lines themselves, during their, often, long history of passages, have been in contact with prion 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 25
agents. If the influenza vaccine-producing cells were able to replicate prions, then contamination during vaccine preparation would be possible. This would have devastating consequences, given that influenza vaccine is distributed to more than 250 million healthy individuals per year.
Prion replication in neuronal cell lines was first demonstrated in 1970 [36] and since then several studies have established that prion inoculation of certain neuronal cell lines results in propagation of infectivity and accumulation of the pathological isoform of the prion protein, PrP Sc [37, 38] . One of the most commonly used cell line for in vitro prion studies is the mouse neuroblastoma cell line N2a which is readily susceptible to mouse adapted sheep scrapie prion strains. In fact, these cells can become chronically infected with the prion agent and have served as an in vitro model for testing potential therapeutic approaches against prion diseases [21, 39] . Several recent reports demonstrated that non-neuronal cells can also support TSE infection. Formation of PrP Sc and scrapie infectivity after exposure to sheep scrapie agent was detected in rabbit epithelial cells, genetically engineered to express significant levels of sheep prion protein [40] . Moreover, the common laboratory fibroblast cell lines 3T3-NIH and L929 were found to be susceptible to infection with mouse-adapted scrapie [12] . Most recently, scrapie infection of murine C2C12 myoblasts and myotubes in vitro following co-culture with scrapie-infected N2a cells was demonstrated, albeit infection did not occur after incubation with a scrapie-infected non-neuronal cell line or a scrapie brain homogenate [41] . The above findings indicate that any cell type that expresses the cellular prion protein (PrP C ) may be capable of supporting prion-replication.
MDCK cells originated from a dog kidney. They were found to express detectable but low levels of canine PrP C (cPrP C ). These were estimated in the range of 2-5ng of PrP such as cheetahs and pumas are highly susceptible to TSE infection [44] . It is reasonable to assume that canine species have also been exposed to BSEcontaminated feed, yet they seem to be immune to infection.
This apparent resistance of canine species to prion infection could result from unique structural features in cPrP C . In a recent study both the primary sequences as well as the three dimensional structures of cPrP C to feline PrP C (fPrP C ) were compared. Four amino acid substitutions between the globular domains of cPrP C and fPrP C were found, all of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 29 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 31 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 32 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 33 22 and 780 have no effect on the translation product, since the first one is located outside of the coding region, whereas the second one is a silent mutation. Mutations at positions 352 and 540 encode for an amino acid substitution, which is shown in Figure   1C . All three MDCK cell lines had identical DNA sequences.
Supplementary Figure 3: Limit of detection of RML-infected cell lysate.
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